Director Steve Liapis resigns from Kyverna board effective Sept 30, 2025

Kyverna Therapeutics, Inc.

Steve Liapis, Ph.D. notified the board of his resignation effective September 30, 2025.
Resignation is not due to any disagreement with the company's operations, policies, or practices.
Board size will be reduced from eight to seven directors upon resignation.
Christi Shaw, a current board member, appointed to the Audit Committee to fill the vacancy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.